See 1999.

Methods	Allocation: randomised (no further description). Blindness: double (no further description). Duration: 5 weeks (preceeded by 3 weeks prestudy stablisation with trifluoperazine 20‐30 mg/day. This was reduced to 5‐10mg/day during week 1 and discontinued during week 2). Consent: given. Setting: hospital.
Participants	Diagnosis: schizophrenia (DSM‐IV). N=20. Age: >18 years. Sex: 14M, 6F. History: chronic, partial responders to neuroleptics, residual sypmptoms. Exclusions: not stated.
Interventions	1. Risperidone: 4‐6 mg/day. N=10. 2. Haloperidol: 15‐30 mg/day. N=10. Benztropine mesylate as required.
Outcomes	Mental state: PANSS. Adverse effects: SAS. Leaving the study early.*
Notes	* Not stated, assumed to be zero.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear